Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Core Insights - Versant Ventures has launched Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for serious diseases [1] - The company has secured over $70 million in committed funding, including a $50 million upfront capital collaboration with Biogen Inc. [1] - Dayra Therapeutics emerged from Versant's Frontier Discovery Engine, which operates in Toronto and Montreal [1]